Targeting fibrosis: Mechanisms and clinical trials

M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications

AZ Mirza, II Althagafi, H Shamshad - European journal of medicinal …, 2019 - Elsevier
The peroxisome proliferator-activated receptors (PPAR-α, PPAR-β/δ, and PPAR-γ) are
members of the nuclear receptor super-family, acting as ligand-inducible transcription …

[HTML][HTML] PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases

Y Lin, Y Wang, P Li - Frontiers in Endocrinology, 2022 - frontiersin.org
Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription
factor that is involved in lipid metabolism of various tissues. Different metabolites of fatty …

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

R Akbari, T Behdarvand, R Afarin, H Yaghooti… - BMC Pharmacology and …, 2021 - Springer
Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) have become significant global health concerns. In the present study, we aimed to …

Impact of fenofibrate on NAFLD/NASH: A genetic perspective

A Mahmoudi, T Jamialahmadi, TP Johnston… - Drug discovery today, 2022 - Elsevier
Highlights•NAFLD is highly prevalent and affects at least one-third of the global
population.•Currently, there is no drug to cure NAFLD.•Fenofibrate is a PPARα agonist with …

Liver protective effect of fenofibrate in NASH/NAFLD animal models

A Mahmoudi, SA Moallem, TP Johnston… - PPAR …, 2022 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver,
affecting around 35% of the world population. Various circumstances contribute to the …

Peroxisome proliferator-activated receptor gamma (PPARγ) as a target for concurrent management of diabetes and obesity-related cancer

Q Wang, M Umar Imam, Z Yida… - Current Pharmaceutical …, 2017 - ingentaconnect.com
Background: Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the
nuclear receptor superfamily of ligand-inducible transcription factors that regulate …

Saroglitazar deactivates the hepatic LPS/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion/LPS model-induced non …

NF Hassan, SA Nada, A Hassan, MR El-Ansary… - Inflammation, 2019 - Springer
The most epidemic liver disorder non-alcoholic steatohepatitis (NASH) is characterized by
hepatic steatosis and inflammation with hepatocellular damage. Recently, it is predictable to …

The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion

AHF Shehata, ASF Ahmed, AB Abdelrehim, GH Heeba - Life sciences, 2020 - Elsevier
Aim The neuronal damage and accompanied functional deficits induced by cerebral
ischemia are among the most common causes of disabilities in adults. Activation of subtypes …

Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

M Yaghoubi, S Jafari, B Sajedi, S Gohari… - European Journal of …, 2017 - journals.lww.com
Results According to the results of this study, 90 patients with NAFLD were divided into three
groups of 30 patients. All variables at the beginning of the study showed no significant …